No Data
Guobang Pharma Unit's Florfenicol Production Passes US FDA Inspection
Guobang Pharmaceutical (605507): Steady and enterprising with an upward cycle.
Both Active Pharmaceutical Ingredients and feed additives are equally important, driving steady growth. Guobang Pharmaceutical focuses on pharmaceutical and chemical technology, based on "one system and two platforms," engaging in the research, production, and Operation of feed additives and key pharmaceutical intermediates.
Express News | Guobang Pharmaceutical: Subsidiary ShanDong Guobang passed the on-site inspection by the USA FDA.
Guobang Pharmaceutical (605507.SH) has repurchased a total of 1.11% of its shares, spending approximately 0.101 billion yuan.
Guobang Pharmaceuticals (605507.SH) announced that as of November 30, 2024, the company has through centralized bidding...
Guobang Pharmaceuticals (605507): From Scale to Growth
Investment key sentence logic: Large-tonnage active pharmaceutical ingredient companies reflecting scale advantages, the recovery of the animal health business is expected to drive performance beyond expectations. Fundamental: Pharmaceuticals stabilize growth, animal health expected to recover. 1. Pharmaceutical business: Volume and price rises, expansion expected. The company's large cyclic internal esters.
Guobang Pharmaceutical (605507.SH): Zhejiang Min Investment Henghua, Silk Road Fund have cumulatively reduced their shareholding by 2.56%.
Country Health Pharmaceuticals (605507.SH) announced on November 29th that the company received a Notice of Shareholding Reduction Results from Zhejiang Civilian Investment Henghua and Silk Road Fund on November 29, 2024. As of November 29, 2024, Zhejiang Civilian Investment Henghua and Silk Road Fund collectively reduced the company's shares by 14,303,883 shares, accounting for 2.56% of the total share capital of the company. The shareholding reduction plan has been completed.